CTOs on the Move

Renovacor

www.renovacor.com

 
Renovacor is a preclinical gene therapy company developing a pipeline of innovative and proprietary AAV based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor`s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kumar Dhanasekharan
 Senior Vice President of Technical Operations Profile

Funding

Renovacor raised $11M on 08/15/2019

Similar Companies

Hydra Biosciences

Hydra Biosciences is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Transgene

Transgene SA is a France-based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases. The company has subsidiaries in China and in the USA.

British Columbia Cancer Agcy

British Columbia Cancer Agcy is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CellzDirect Inc

CellzDirect Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.